Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $11.67

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have earned an average rating of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $11.6667.

A number of equities analysts have issued reports on ACRV shares. Jefferies Financial Group reissued a “buy” rating on shares of Acrivon Therapeutics in a research report on Monday, March 2nd. Wall Street Zen lowered shares of Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, March 1st. Finally, Weiss Ratings raised shares of Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, April 27th.

Acrivon Therapeutics Price Performance

Shares of ACRV stock opened at $1.92 on Friday. The firm has a market capitalization of $82.18 million, a price-to-earnings ratio of -0.96 and a beta of 2.01. The business has a fifty day moving average of $1.69 and a 200 day moving average of $1.94. Acrivon Therapeutics has a 1 year low of $1.05 and a 1 year high of $3.56.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its earnings results on Wednesday, May 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.49). As a group, equities research analysts expect that Acrivon Therapeutics will post -2 earnings per share for the current year.

Hedge Funds Weigh In On Acrivon Therapeutics

Institutional investors have recently modified their holdings of the stock. Schonfeld Strategic Advisors LLC purchased a new position in shares of Acrivon Therapeutics during the 4th quarter valued at about $40,000. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Acrivon Therapeutics during the 4th quarter valued at about $44,000. Focus Partners Wealth purchased a new position in shares of Acrivon Therapeutics during the 3rd quarter valued at about $36,000. Quadrature Capital Ltd purchased a new position in shares of Acrivon Therapeutics during the 4th quarter valued at about $50,000. Finally, Invesco Ltd. purchased a new position in shares of Acrivon Therapeutics during the 1st quarter valued at about $72,000. Hedge funds and other institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.